Immunovant Inc Total Liabilities
Immunovant Inc total liabilities. Based on the latest financial reports, Immunovant Inc (IMVT) has total liabilities worth $117.10 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Immunovant Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immunovant Inc (2018–2026)
Total liabilities of Immunovant Inc from 2018 to 2026. This chart illustrates how Immunovant Inc's total liabilities have evolved over time, based on quarterly financial data.
Immunovant Inc Competitors by Total Liabilities
The table below lists competitors of Immunovant Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YTL Corporation Bhd
KLSE:4677
|
Malaysia | RM69.98 Billion |
|
Accelleron Industries AG
SW:ACLN
|
Switzerland | CHF1.06 Billion |
|
Zhuzhou CRRC Times Electric Co Ltd
SHG:688187
|
China | CN¥26.16 Billion |
|
Dongxing Sec Co Ltd
SHG:601198
|
China | CN¥86.75 Billion |
|
News Corp B
NASDAQ:NWS
|
USA | $6.05 Billion |
|
Weatherford International plc
NASDAQ:WFRD
|
USA | $3.50 Billion |
|
Belite Bio Inc ADR
NASDAQ:BLTE
|
USA | $14.95 Million |
|
Shenzhen Kaifa Technology Co Ltd
SHE:000021
|
China | CN¥11.86 Billion |
Liability Composition Analysis (2018–2026)
This chart breaks down Immunovant Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Immunovant Inc assets under control.
Liquidity & Leverage Metrics
Immunovant Inc Total Liabilities Ratios Explained
Immunovant Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunovant Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunovant Inc (2018–2026)
The table below shows the annual total liabilities of Immunovant Inc from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $104.97 Million | +52.64% |
| 2025-03-31 | $68.78 Million | +40.49% |
| 2024-03-31 | $48.95 Million | +12.95% |
| 2023-03-31 | $43.34 Million | -5.24% |
| 2022-03-31 | $45.74 Million | +117.71% |
| 2021-03-31 | $21.01 Million | +37.15% |
| 2020-03-31 | $15.32 Million | +3926.31% |
| 2019-03-31 | $380.45K | -76.37% |
| 2018-03-31 | $1.61 Million | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more